Compare KEQU & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KEQU | AMRN |
|---|---|---|
| Founded | 1906 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 287.9M |
| IPO Year | 1995 | 1998 |
| Metric | KEQU | AMRN |
|---|---|---|
| Price | $34.14 | $13.82 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 1.6K | ★ 79.6K |
| Earning Date | 03-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | ★ 3.22 | N/A |
| Revenue | $138,558,000.00 | ★ $181,104,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.26 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | 7.72 | ★ 39.22 |
| 52 Week Low | $33.27 | $12.96 |
| 52 Week High | $46.70 | $20.90 |
| Indicator | KEQU | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 49.03 |
| Support Level | $33.49 | $13.59 |
| Resistance Level | $35.35 | $14.55 |
| Average True Range (ATR) | 0.95 | 0.54 |
| MACD | -0.30 | 0.04 |
| Stochastic Oscillator | 34.29 | 41.36 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.